Frattini V, Pagnotta S, Tala -, Fan J, Russo M, Lee S, et al. A metabolic function of FGFR3-TACC3 gene fusions in cancer. Nature. 2018;553:222-227 pubmed publisher

Koole K, van Kempen P, Swartz J, Peeters T, van Diest P, Koole R, et al. Fibroblast growth factor receptor 3 protein is overexpressed in oral and oropharyngeal squamous cell carcinoma. Cancer Med. 2016;5:275-84 pubmed publisher

Park S, Nam S, Keam B, Kim T, Jeon Y, Lee S, et al. VEGF and Ki-67 Overexpression in Predicting Poor Overall Survival in Adenoid Cystic Carcinoma. Cancer Res Treat. 2016;48:518-26 pubmed publisher

Mansoor A, Akhter A, Pournazari P, Mahe E, Shariff S, Farooq F, et al. Protein Expression for Novel Prognostic Markers (Cyclins D1, D2, D3, B1, B2, ITGβ7, FGFR3, PAX5) Correlate With Previously Reported Gene Expression Profile Patterns in Plasma Cell Myeloma. Appl Immunohistochem Mol Morphol. 2015;23:327-33 pubmed publisher

Kossack N, Terwort N, Wistuba J, Ehmcke J, Schlatt S, Scholer H, et al. A combined approach facilitates the reliable detection of human spermatogonia in vitro. Hum Reprod. 2013;28:3012-25 pubmed publisher

Alijaj N, Moutel S, Gouveia Z, Gray M, Roveri M, Dzhumashev D, et al. Novel FGFR4-Targeting Single-Domain Antibodies for Multiple Targeted Therapies against Rhabdomyosarcoma. Cancers (Basel). 2020;12: pubmed publisher

Lima N, Atkinson E, Bunney T, Katan M, Huang P. Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations. Int J Mol Sci. 2020;21: pubmed publisher

Guo J, Grow E, Mlcochova H, Maher G, Lindskog C, Nie X, et al. The adult human testis transcriptional cell atlas. Cell Res. 2018;28:1141-1157 pubmed publisher

Best S, Harapas C, Kersbergen A, Rathi V, Asselin Labat M, Sutherland K. FGFR3-TACC3 is an oncogenic fusion protein in respiratory epithelium. Oncogene. 2018;37:6096-6104 pubmed publisher

Lee C, Moon S, Jeong J, Lee S, Lee M, Yoo S, et al. Kaempferol targeting on the fibroblast growth factor receptor 3-ribosomal S6 kinase 2 signaling axis prevents the development of rheumatoid arthritis. Cell Death Dis. 2018;9:401 pubmed publisher

Lehtinen B, Raita A, Kesseli J, Annala M, Nordfors K, Yli Harja O, et al. Clinical association analysis of ependymomas and pilocytic astrocytomas reveals elevated FGFR3 and FGFR1 expression in aggressive ependymomas. BMC Cancer. 2017;17:310 pubmed publisher

Guancial E, Werner L, Bellmunt J, Bamias A, Choueiri T, Ross R, et al. FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. Cancer Med. 2014;3:835-44 pubmed publisher

Xie Z, Gunaratne J, Cheong L, Liu S, Koh T, Huang G, et al. Plasma membrane proteomics identifies biomarkers associated with MMSET overexpression in T(4;14) multiple myeloma. Oncotarget. 2013;4:1008-18 pubmed

Herrera Abreu M, Pearson A, Campbell J, Shnyder S, Knowles M, Ashworth A, et al. Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer. Cancer Discov. 2013;3:1058-71 pubmed publisher

Balbás Martínez C, Rodriguez Pinilla M, Casanova A, Dominguez O, Pisano D, Gomez G, et al. ARID1A alterations are associated with FGFR3-wild type, poor-prognosis, urothelial bladder tumors. PLoS ONE. 2013;8:e62483 pubmed publisher

Ishigami T, Hida Y, Matsudate Y, Murao K, Kubo Y. The involvement of fibroblast growth factor receptor signaling pathways in dermatofibroma and dermatofibrosarcoma protuberans. J Med Invest. 2013;60:106-13 pubmed

von Kopylow K, Staege H, Schulze W, Will H, Kirchhoff C. Fibroblast growth factor receptor 3 is highly expressed in rarely dividing human type A spermatogonia. Histochem Cell Biol. 2012;138:759-72 pubmed publisher

Wilson T, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature. 2012;487:505-9 pubmed publisher

Marshall M, Hinz T, Kono S, Singleton K, Bichon B, Ware K, et al. Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells. Clin Cancer Res. 2011;17:5016-25 pubmed publisher

Ware K, Marshall M, Heasley L, Marek L, Hinz T, Hercule P, et al. Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression. PLoS ONE. 2010;5:e14117 pubmed publisher

Zingone A, Cultraro C, Shin D, Bean C, Morse H, Janz S, et al. Ectopic expression of wild-type FGFR3 cooperates with MYC to accelerate development of B-cell lineage neoplasms. Leukemia. 2010;24:1171-8 pubmed publisher

Hida Y, Kubo Y, Nishio Y, Murakami S, Fukumoto D, Sayama K, et al. Malignant acanthosis nigricans with enhanced expression of fibroblast growth factor receptor 3. Acta Derm Venereol. 2009;89:435-7 pubmed publisher

Karlou M, Saetta A, Korkolopoulou P, Levidou G, Papanastasiou P, Boltetsou E, et al. Activation of extracellular regulated kinases (ERK1/2) predicts poor prognosis in urothelial bladder carcinoma and is not associated with B-Raf gene mutations. Pathology. 2009;41:327-34 pubmed publisher

Hida Y, Kubo Y, Arase S. Activation of fibroblast growth factor receptor 3 and oncogene-induced senescence in skin tumours. Br J Dermatol. 2009;160:1258-63 pubmed publisher

Dawson M, Opat S, Taouk Y, Donovan M, Zammit M, Monaghan K, et al. Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myeloma. Clin Cancer Res. 2009;15:714-22 pubmed publisher

Larson A, Cook J. Fibroblast growth factor receptor 3 (FGFR3) expression in malignant lymphomas. Appl Immunohistochem Mol Morphol. 2008;16:322-5 pubmed publisher

Chang H, Stewart A, Qi X, Li Z, Yi Q, Trudel S. Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma. Blood. 2005;106:353-5 pubmed